Kitov Pharma Ltd. (SEC Filing Page | XBRL Cloud Viewer | XBRL Instance)

Line Label Object Class Period Type Balance Report ElementName
1 001 - Document - Document and Entity Information Network

*

*

 http://kitovpharma.com/role/DocumentAndEntityInformation
2 Implied Table Table

*

*

 implied:Table
3 Document and Entity Information [Abstract] Abstract ktov:DocumentAndEntityInformationAbstract
4 Entity Registrant Name Concept (Text/String) For Period dei:EntityRegistrantName
5 Entity Central Index Key Concept (CIK Number) For Period dei:EntityCentralIndexKey
6 Amendment Flag Concept (Yes/No) For Period dei:AmendmentFlag
7 Trading Symbol Concept (Text/String) For Period dei:TradingSymbol
8 Current Fiscal Year End Date Concept (Month/Day) For Period dei:CurrentFiscalYearEndDate
9 Document Type Concept (Submission Type) For Period dei:DocumentType
10 Document Period End Date Concept (Date) For Period dei:DocumentPeriodEndDate
11 Document Fiscal Period Focus Concept (Fiscal Period) For Period dei:DocumentFiscalPeriodFocus
12 Document Fiscal Year Focus Concept (Year) For Period dei:DocumentFiscalYearFocus
13 Entity Well-known Seasoned Issuer Concept (Yes/No) For Period dei:EntityWellKnownSeasonedIssuer
14 Entity Voluntary Filers Concept (Yes/No) For Period dei:EntityVoluntaryFilers
15 Entity Current Reporting Status Concept (Yes/No) For Period dei:EntityCurrentReportingStatus
16 Entity Filer Category Concept (Filer Category) For Period dei:EntityFilerCategory
17 Entity Emerging Growth Company Concept (Yes/No) For Period dei:EntityEmergingGrowthCompany
18 Entity Ex Transition Period Concept (Yes/No) For Period dei:EntityExTransitionPeriod
19 Entity Shell Company Concept (Yes/No) For Period dei:EntityShellCompany
20 Entity Common Stock, Shares Outstanding Concept (Shares) As Of dei:EntityCommonStockSharesOutstanding
21 002 - Statement - Consolidated Statements of Financial Position Network

*

*

 http://kitovpharma.com/role/ConsolidatedStatementsOfFinancialPosition
22 Implied Table Table

*

*

 implied:Table
23 Statement of financial position [abstract] Abstract ifrs-full:StatementOfFinancialPositionAbstract
24 Assets Abstract ifrs-full:AssetsAbstract
25 Cash and cash equivalents Concept (Monetary) As Of Debit ifrs-full:CashAndCashEquivalents
26 Short term deposits Concept (Monetary) As Of Debit ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents
27 Other current assets Concept (Monetary) As Of Debit ifrs-full:OtherCurrentAssets
28 Total current assets Concept (Monetary) As Of Debit ifrs-full:CurrentAssets
29 Fixed assets, net Concept (Monetary) As Of Debit ifrs-full:PropertyPlantAndEquipment
30 Intangible assets Concept (Monetary) As Of Debit ifrs-full:IntangibleAssetsOtherThanGoodwill
31 Total assets Concept (Monetary) As Of Debit ifrs-full:Assets
32 Liabilities Abstract ifrs-full:LiabilitiesAbstract
33 Accounts payable Concept (Monetary) As Of Credit ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers
34 Other payables Concept (Monetary) As Of Credit ifrs-full:OtherCurrentPayables
35 Derivative instruments Concept (Monetary) As Of Credit ifrs-full:CurrentDerivativeFinancialLiabilities
36 Total current liabilities Concept (Monetary) As Of Credit ifrs-full:CurrentLiabilities
37 Non-current liabilities Abstract ifrs-full:NoncurrentLiabilitiesAbstract
38 Derivative instruments Concept (Monetary) As Of Credit ifrs-full:NoncurrentDerivativeFinancialLiabilities
39 Post-employment benefit liabilities Concept (Monetary) As Of Credit ifrs-full:NoncurrentProvisionsForEmployeeBenefits
40 Total non - current liabilities Concept (Monetary) As Of Credit ifrs-full:NoncurrentLiabilities
41 Equity Abstract ifrs-full:EquityAbstract
42 Share capital, no par value Concept (Monetary) As Of Credit ifrs-full:IssuedCapital
43 Share premium Concept (Monetary) As Of Credit ifrs-full:SharePremium
44 Receipts on account of warrants Concept (Monetary) As Of Credit ktov:ReceiptsOnAccountsOfWarrant
45 Capital reserve for share-based payments Concept (Monetary) As Of Credit ifrs-full:ReserveOfSharebasedPayments
46 Capital reserve from transactions with related parties Concept (Monetary) As Of Credit ifrs-full:CapitalReserve
47 Capital reserve from transactions with non- controlling interest Concept (Monetary) As Of Credit ktov:CapitalReserveFromTransactionsWithNon-ControllingInterest
48 Accumulated loss Concept (Monetary) As Of Credit ifrs-full:RetainedEarnings
49 Equity attributable to owners of the Company Concept (Monetary) As Of Credit ifrs-full:EquityAttributableToOwnersOfParent
50 Non-controlling interests Concept (Monetary) As Of Credit ifrs-full:NoncontrollingInterests
51 Total equity Concept (Monetary) As Of Credit ifrs-full:Equity
52 Total liabilities and equity Concept (Monetary) As Of Credit ifrs-full:EquityAndLiabilities
53 003 - Statement - Consolidated Statements of Operations and Other Comprehensive Income Network

*

*

 http://kitovpharma.com/role/ConsolidatedStatementsOfOperationsAndOtherComprehensiveIncome
54 Implied Table Table

*

*

 implied:Table
55 Profit or loss [abstract] Abstract ifrs-full:IncomeStatementAbstract
56 Revenues Concept (Monetary) For Period Credit ifrs-full:Revenue
57 Research and development expenses Concept (Monetary) For Period Debit ifrs-full:ResearchAndDevelopmentExpense
58 General and administrative expenses Concept (Monetary) For Period Debit ifrs-full:GeneralAndAdministrativeExpense
59 Reimbursement of legal fees Concept (Monetary) For Period Credit ifrs-full:FeeAndCommissionIncome
60 Other expenses (income) Concept (Monetary) For Period Credit ktov:OtherIncomeExpenseByFunction
61 Total operating expenses Concept (Monetary) For Period Debit ifrs-full:OperatingExpense
62 Operating Loss Concept (Monetary) For Period Credit ifrs-full:ProfitLossFromOperatingActivities
63 Net change in fair value of derivatives Concept (Monetary) For Period Credit ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives
64 Finance expense Concept (Monetary) For Period Debit ifrs-full:FinanceCosts
65 Finance income Concept (Monetary) For Period Credit ifrs-full:FinanceIncome
66 Finance expenses (income), net Concept (Monetary) For Period Debit ktov:FinanceExpensesNet
67 Loss for the year Concept (Monetary) For Period Credit ifrs-full:ProfitLossFromContinuingOperations
68 Other comprehensive loss Abstract ifrs-full:OtherComprehensiveIncomeAbstract
69 Re-measurement of defined benefit liability Concept (Monetary) For Period Debit ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset
70 Total comprehensive loss for the year Concept (Monetary) For Period Credit ifrs-full:ComprehensiveIncome
71 Loss attributable to: Abstract ifrs-full:ProfitLossAttributableToAbstract
72 Owners of the Company Concept (Monetary) For Period Credit ifrs-full:ProfitLossAttributableToOwnersOfParent
73 Non-controlling interests Concept (Monetary) For Period Credit ifrs-full:ProfitLossAttributableToNoncontrollingInterests
74 Total Loss attributable Concept (Monetary) For Period Credit ktov:ProfitLossAttributableToOwnersAndIncludingNonControllingInterests
75 Total comprehensive loss attributable to: Abstract ifrs-full:ComprehensiveIncomeAttributableToAbstract
76 Owners of the Company Concept (Monetary) For Period Credit ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent
77 Non-controlling interests Concept (Monetary) For Period Credit ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests
78 Non-controlling interests Concept (Monetary) For Period Credit ifrs-full:ComprehensiveIncome
79 Loss per share data Abstract ifrs-full:BasicEarningsPerShareAbstract
80 Basic and diluted loss per share - USD Concept (Share) For Period ifrs-full:BasicAndDilutedEarningsLossPerShare
81 Number of shares used in calculating basic and diluted loss per share Concept (Shares) For Period ifrs-full:WeightedAverageShares
82 004 - Statement - Consolidated Statements of Changes in Equity Network

*

*

 http://kitovpharma.com/role/ConsolidatedStatementsOfChangesInEquity
83 Statement of changes in equity [table] Table

*

*

 ifrs-full:StatementOfChangesInEquityTable
84 Components of equity [axis] Axis ifrs-full:ComponentsOfEquityAxis
85 Equity [member] Member ifrs-full:EquityMember
86 Share Capital Member ifrs-full:IssuedCapitalMember
87 Share premium Member ifrs-full:SharePremiumMember
88 Receipts on account of warrants Member ktov:ReceiptsOnAccountOfWarrantMember
89 Capital reserve for share-based payments Member ifrs-full:ReserveOfSharebasedPaymentsMember
90 Capital reserve from transactions with related parties Member ktov:CapitalReserveFromTransactionsWithRelatedPartiesMember
91 Capital reserve from transactions with Non-controlling interest [Member] Member ktov:CapitalReserveFromTransactionsWithNon-ControllingInterestMember
92 Accumulated loss Member ifrs-full:RetainedEarningsMember
93 Total equity Member ifrs-full:EquityAttributableToOwnersOfParentMember
94 Non-controlling interests Member ifrs-full:NoncontrollingInterestsMember
95 Statement of changes in equity [line items] LineItems ifrs-full:StatementOfChangesInEquityLineItems
96 Balance Concept (Monetary) As Of Credit ifrs-full:Equity
97 Transactions with owners of the company: Abstract ktov:TransactionsWithOwnersAbstract
98 Issuance of American Depository Shares (ADSs) on the NASDAQ, net of issuance costs Concept (Monetary) For Period Credit ktov:IssuanceOfAmericanDepositorySharesNetOfIssuanceCosts
99 Issuance of shares due to RSUs vesting Concept (Monetary) For Period Credit ktov:StockIssuedDuringPeriodValueRestrictedStockUnitVesting
100 Issuance of shares due to RSUs vesting, shares Concept (Shares) For Period ktov:StockIssuedDuringPeriodSharesRestrictedStockUnitVesting
101 Exercise of warrants Concept (Monetary) For Period Credit ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
102 Share issuance due to an acquisition of a subsidiary (see Note 5) Concept (Monetary) For Period Credit ktov:ShareIssuanceDueToAcquisitionOfSubsidiary
103 Share-based payments Concept (Monetary) For Period Credit ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
104 Transfer of derivative instrument from liability to equity Concept (Monetary) For Period Credit ktov:TransferOfDerivativeInstrumentFromLiabilityToEquity
105 Issuance of shares, net of issuance costs Concept (Monetary) For Period Debit ifrs-full:ShareIssueRelatedCost
106 Issuance of warrants, net of issuance costs Concept (Monetary) For Period Credit ktov:IssuanceOfWarrantsNetOfIssuanceCosts
107 Share issuance due to a development agreement Concept (Monetary) For Period Credit ktov:ShareIssuanceDueToStrategicCooperationAgreement
108 Exercise of warrants (series B) Concept (Monetary) For Period Credit ktov:IncreaseDecreaseThroughExerciseOfWarrantsOneEquity
109 Exercise and expiration of warrants (series 1) Concept (Monetary) For Period Credit ktov:IncreaseDecreaseThroughExerciseOfWarrantsTwoEquity
110 Exercise of warrants (series 2) Concept (Monetary) For Period Credit ktov:IncreaseDecreaseThroughExerciseOfWarrantsThreeEquity
111 Total transactions with owners of the Company Concept (Monetary) For Period Credit ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
112 Comprehensive loss for the year: Abstract ifrs-full:ComprehensiveIncomeAbstract
113 Loss for the year Concept (Monetary) For Period Credit ifrs-full:ProfitLoss
114 Other comprehensive loss Concept (Monetary) For Period Credit ifrs-full:OtherComprehensiveIncome
115 Total comprehensive loss for the year Concept (Monetary) For Period Credit ifrs-full:ComprehensiveIncome
116 Balance Concept (Monetary) As Of Credit ifrs-full:Equity
117 005 - Statement - Consolidated Statements of Cash Flows Network

*

*

 http://kitovpharma.com/role/ConsolidatedStatementsOfCashFlows
118 Implied Table Table

*

*

 implied:Table
119 Statement of cash flows [abstract] Abstract ifrs-full:StatementOfCashFlowsAbstract
120 Cash flows from operating activities: Abstract ifrs-full:CashFlowsFromUsedInOperatingActivitiesAbstract
121 Loss for the year Concept (Monetary) For Period Credit ifrs-full:ProfitLoss
122 Adjustments: Abstract ifrs-full:AdjustmentsForReconcileProfitLossAbstract
123 Depreciation Concept (Monetary) For Period Debit ifrs-full:AdjustmentsForDepreciationExpense
124 Finance expenses (income), net Concept (Monetary) For Period Debit ifrs-full:AdjustmentsForFinanceCosts
125 Share-based payments Concept (Monetary) For Period Debit ifrs-full:AdjustmentsForSharebasedPayments
126 Expenses (income) in regards with settlement with a minority shareholder of a subsidiary (see Note 5B) Concept (Monetary) For Period Debit ktov:AdjustmentForSettlementMinorityShareholderOfSubsidiary
127 Expenses in regard to a strategic cooperation agreement Concept (Monetary) For Period Debit ktov:AdjustmentsForExpensesInRegardToStrategicCooperationAgreement
128 Total adjustments Concept (Monetary) For Period Debit ifrs-full:AdjustmentsForReconcileProfitLoss
129 Changes in assets and liabilities: Abstract ktov:ChangesInAssetsAndLiabilitiesAbstract
130 Changes in other receivables Concept (Monetary) For Period Debit ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables
131 Changes in accounts payable Concept (Monetary) For Period Debit ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable
132 Changes in other payables Concept (Monetary) For Period Debit ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables
133 Changes in post-employment benefit liabilities Concept (Monetary) For Period Debit ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities
134 Changes in assets and liabilities, total Concept (Monetary) For Period Debit ktov:AdjustmentsForChangesInAssetsAndLiabilities
135 Net cash used in operating activities Concept (Monetary) For Period ifrs-full:CashFlowsFromUsedInOperatingActivities
136 Cash flows from investing activities: Abstract ifrs-full:CashFlowsFromUsedInInvestingActivitiesAbstract
137 Acquisition of a subsidiary (see Note 5) Concept (Monetary) For Period Debit ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments
138 Decrease (increase) in short term deposits Concept (Monetary) For Period Debit ifrs-full:CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013
139 Interest received Concept (Monetary) For Period Debit ktov:InterestReceivedClassifiedAsFinancingActivities
140 Acquisition of fixed assets Concept (Monetary) For Period Credit ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
141 Net cash provided by (used in) investing activities Concept (Monetary) For Period Debit ifrs-full:CashFlowsFromUsedInInvestingActivities
142 Cash flows from financing activities: Abstract ifrs-full:CashFlowsFromUsedInFinancingActivitiesAbstract
143 Repayment of loans from related parties Concept (Monetary) For Period Credit ktov:RepaymentsOfLoansFromRelatedPartiesClassifiedAsFinancingActivities
144 Short-term credit from bank Concept (Monetary) For Period Debit ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities
145 Proceeds from issuance of ADSs Concept (Monetary) For Period Debit ifrs-full:ProceedsFromIssuingShares
146 Share and ADS issuance expenses paid Concept (Monetary) For Period Credit ktov:ShareAndAdsIssuanceExpensesPaid
147 Proceeds from issuance of warrants Concept (Monetary) For Period Debit ktov:ProceedsFromIssuingWarrants
148 Warrants issuance expenses paid Concept (Monetary) For Period Credit ktov:WarrantsIssuanceExpensesPaid
149 Receipts from warrant exercise Concept (Monetary) For Period Debit ktov:ReceiptsFromWarrantExercise
150 Interest paid Concept (Monetary) For Period Credit ifrs-full:InterestPaidClassifiedAsFinancingActivities
151 Net cash provided by financing activities: Concept (Monetary) For Period Debit ifrs-full:CashFlowsFromUsedInFinancingActivities
152 Net increase (decrease) in cash and cash equivalents Concept (Monetary) For Period Debit ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges
153 Cash and cash equivalents at the beginning of the year Concept (Monetary) As Of Debit ifrs-full:CashAndCashEquivalents
154 Effect of translation adjustments on cash Concept (Monetary) For Period Debit ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents
155 Cash and cash equivalents at end of the year Concept (Monetary) As Of Debit ifrs-full:CashAndCashEquivalents
156 006 - Disclosure - General Network

*

*

 http://kitovpharma.com/role/General
157 Implied Table Table

*

*

 implied:Table
158 General [Abstract] Abstract ktov:GeneralAbstract
159 General Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory
160 007 - Disclosure - Basis of Preparation of the Financial Statements Network

*

*

 http://kitovpharma.com/role/BasisOfPreparationOfFinancialStatements
161 Implied Table Table

*

*

 implied:Table
162 Basis of Preparation of the Financial Statements [Abstract] Abstract ktov:BasisOfPreparationOfFinancialStatementsAbstract
163 Basis of Preparation of the Financial Statements Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory
164 008 - Disclosure - Significant Accounting Policies Network

*

*

 http://kitovpharma.com/role/SignificantAccountingPolicies
165 Implied Table Table

*

*

 implied:Table
166 Significant Accounting Policies [Abstract] Abstract ktov:SignificantAccountingPoliciesAbstract
167 Significant Accounting Policies Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory
168 009 - Disclosure - Operating Segments Network

*

*

 http://kitovpharma.com/role/OperatingSegments
169 Implied Table Table

*

*

 implied:Table
170 Operating Segments [Abstract] Abstract ifrs-full:DisclosureOfOperatingSegmentsAbstract
171 Operating Segments Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfOperatingSegmentsExplanatory
172 010 - Disclosure - Subsidiary Network

*

*

 http://kitovpharma.com/role/AcquisitionOfSubsidiary
173 Implied Table Table

*

*

 implied:Table
174 Subsidiary [Abstract] Abstract ktov:SubsidiariesAbstract
175 Subsidiary Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory
176 011 - Disclosure - Cash and Cash Equivalents Network

*

*

 http://kitovpharma.com/role/CashAndCashEquivalents
177 Implied Table Table

*

*

 implied:Table
178 Cash and Cash Equivalents [Abstract] Abstract ifrs-full:CashAndCashEquivalentsAbstract
179 Cash and Cash Equivalents Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory
180 012 - Disclosure - Other Current Assets Network

*

*

 http://kitovpharma.com/role/OtherCurrentAssets
181 Implied Table Table

*

*

 implied:Table
182 Other Current Assets [Abstract] Abstract ktov:OtherCurrentAssetsAbstract
183 Other Current Assets Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory
184 013 - Disclosure - Other Payables Network

*

*

 http://kitovpharma.com/role/OtherPayables
185 Implied Table Table

*

*

 implied:Table
186 Other Payables [Abstract] Abstract ifrs-full:TradeAndOtherPayablesAbstract
187 Other Payables Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory
188 014 - Disclosure - Equity Network

*

*

 http://kitovpharma.com/role/Equity
189 Implied Table Table

*

*

 implied:Table
190 Equity [Abstract] Abstract ifrs-full:ChangesInEquityAbstract
191 Equity Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory
192 015 - Disclosure - Share-based Payment Arrangements Network

*

*

 http://kitovpharma.com/role/ShareBasedPaymentArrangements
193 Implied Table Table

*

*

 implied:Table
194 Share-based Payment Arrangements [Abstract] Abstract ktov:ShareBasedPaymentArrangementsAbstract
195 Share-based Payment Arrangements Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory
196 016 - Disclosure - Transactions and Balances with Related Parties Network

*

*

 http://kitovpharma.com/role/TransactionsAndBalancesWithRelatedParties
197 Implied Table Table

*

*

 implied:Table
198 Transactions and Balances with Related Parties [Abstract] Abstract ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesAbstract
199 Transactions and Balances with Related Parties Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory
200 017 - Disclosure - Commitments and Contingent Liabilities Network

*

*

 http://kitovpharma.com/role/CommitmentsAndContingentLiabilities
201 Implied Table Table

*

*

 implied:Table
202 Commitments and Contingent Liabilities [Abstract] Abstract ifrs-full:DisclosureOfContingentLiabilitiesAbstract
203 Commitments and contingent liabilities Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory
204 018 - Disclosure - Revenues Network

*

*

 http://kitovpharma.com/role/Revenues
205 Implied Table Table

*

*

 implied:Table
206 Revenues [Abstract] Abstract ifrs-full:RevenueAbstract
207 Revenues Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfRevenueExplanatory
208 019 - Disclosure - Research and Development Expenses Network

*

*

 http://kitovpharma.com/role/ResearchAndDevelopmentExpenses
209 Implied Table Table

*

*

 implied:Table
210 Research and Development Expenses [Abstract] Abstract ktov:ResearchAndDevelopmentExpensesAbstract
211 Research and Development Expenses Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory
212 020 - Disclosure - General and Administrative Expenses Network

*

*

 http://kitovpharma.com/role/GeneralAndAdministrativeExpenses
213 Implied Table Table

*

*

 implied:Table
214 General and Administrative Expenses [Abstract] Abstract ktov:GeneralAndAdministrativeExpensesAbstract
215 General and Administrative Expenses Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory
216 021 - Disclosure - Other Expenses (Income) Network

*

*

 http://kitovpharma.com/role/OtherExpensesIncome
217 Implied Table Table

*

*

 implied:Table
218 Other Expenses (Income) [Abstract] Abstract ktov:OthersExpensesAbstract
219 Other Expenses (Income) Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfExpensesExplanatory
220 022 - Disclosure - Finance Expense (Income) Network

*

*

 http://kitovpharma.com/role/FinanceExpenseIncome
221 Implied Table Table

*

*

 implied:Table
222 Finance Expense (Income) [Abstract] Abstract ktov:FinanceExpenseIncomeAbstract
223 Finance Expense (Income) Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory
224 023 - Disclosure - Taxes on Income Network

*

*

 http://kitovpharma.com/role/TaxesOnIncome
225 Implied Table Table

*

*

 implied:Table
226 Taxes on Income [Abstract] Abstract ktov:TaxesOnIncomeAbstract
227 Taxes on Income Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfIncomeTaxExplanatory
228 024 - Disclosure - Employee Benefits Network

*

*

 http://kitovpharma.com/role/EmployeeBenefits
229 Implied Table Table

*

*

 implied:Table
230 Employee Benefits [Abstract] Abstract ktov:EmployeeBenefitsAbstract
231 Employee benefits Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfEmployeeBenefitsExplanatory
232 025 - Disclosure - Financial Instruments Network

*

*

 http://kitovpharma.com/role/FinancialInstruments
233 Implied Table Table

*

*

 implied:Table
234 Financial Instruments [Abstract] Abstract ifrs-full:DisclosureOfFinancialInstrumentsAbstract
235 Financial Instruments Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfFinancialInstrumentsExplanatory
236 026 - Disclosure - Subsequent Events Network

*

*

 http://kitovpharma.com/role/SubsequentEvents
237 Implied Table Table

*

*

 implied:Table
238 Subsequent Events [Abstract] Abstract ktov:SubsequentsEventsAbstract
239 Subsequent Events Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory
240 027 - Disclosure - Significant Accounting Policies (Policies) Network

*

*

 http://kitovpharma.com/role/SignificantAccountingPoliciesPolicies
241 Implied Table Table

*

*

 implied:Table
242 Significant Accounting Policies [Abstract] Abstract ktov:SignificantAccountingPoliciesAbstract
243 Basis of consolidation Concept (Text Block (HTML)) For Period ktov:DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock
244 Foreign currency transactions Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory
245 Financial instruments Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForDerivativeFinancialInstrumentsAndHedgingExplanatory
246 Intangible assets Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory
247 Loss per share Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory
248 Employee benefits Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory
249 Share-based payment transactions Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory
250 Provisions Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory
251 Revenue Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue
252 Financing income and expense Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory
253 Equity Concept (Text Block (HTML)) For Period ktov:DescriptionOfAccountingPolicyForEquityPolicyTextBlock
254 Issuance of units of securities Concept (Text Block (HTML)) For Period ktov:DescriptionOfAccountingPolicyForIssuanceOfUnitsOfSecuritiesPolicyTextBlock
255 Deferred tax Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory
256 New standards and interpretations not yet adopted Concept (Text Block (HTML)) For Period ktov:NewStandardsAndInterpretationsNotYetAdoptedPolicyTextBlock
257 028 - Disclosure - Basis of Preparation of the Financial Statements (Tables) Network

*

*

 http://kitovpharma.com/role/BasisofPreparationoftheFinancialStatementsTables
258 Implied Table Table

*

*

 implied:Table
259 Basis of Preparation of the Financial Statements [Abstract] Abstract ktov:BasisOfPreparationOfFinancialStatementsAbstract
260 Schedule of changes in exchange rates Concept (Text Block (HTML)) For Period ktov:DisclosureOfDetailedInformationAboutExchangeRatesAndLinkageBasesExplanatoryTableTextBlock
261 Schedule of expected effect of the standard's application on the relevant items of the statement of financial position Concept (Text Block (HTML)) For Period ktov:DisclosureOfDetailedInformationAboutExpectedEffectOfStandardsApplicationOnRelevantItemsOfStatementOfFinancialPositionTableTextBlock
262 Schedule of expected effect of the standard's application on the relevant items of the statement of operations position Concept (Text Block (HTML)) For Period ktov:DisclosureOfDetailedInformationAboutExpectedEffectOfStandardsApplicationOnRelevantItemsOfStatementOfOperationsTableTextBlock
263 029 - Disclosure - Operating Segments (Tables) Network

*

*

 http://kitovpharma.com/role/OperatingSegmentsTables
264 Implied Table Table

*

*

 implied:Table
265 Operating Segments [Abstract] Abstract ifrs-full:DisclosureOfOperatingSegmentsAbstract
266 Schedule of segment reporting information by segment Concept (Text Block (HTML)) For Period ktov:DisclosureOfDetailedInformationAboutSegmentReportingInformationBySegmentExplanatoryTableTextBlock
267 030 - Disclosure - Subsidiary (Tables) Network

*

*

 http://kitovpharma.com/role/AcquisitionOfSubsidiarytables
268 Implied Table Table

*

*

 implied:Table
269 Subsidiary [Abstract] Abstract ktov:SubsidiariesAbstract
270 Summary of acquisition date fair value of each major class of consideration Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory
271 Schedule of recognized amounts of assets acquired and liabilities assumed at the date of acquisition Concept (Text Block (HTML)) For Period ktov:DisclosureOfDetailedInformationAboutRecognizedAmountOfAssetsAcquiredAndLiabilitiesAssumedExplanatoryTableTextBlock
272 Schedule of condensed information regarding TyrNovo Concept (Text Block (HTML)) For Period ktov:DisclosureOfDetailedInformationAboutSubsidiariesExplanatoryTableTextBlock
273 031 - Disclosure - Cash and Cash Equivalents (Tables) Network

*

*

 http://kitovpharma.com/role/CashandCashEquivalentsTables
274 Implied Table Table

*

*

 implied:Table
275 Cash and Cash Equivalents [Abstract] Abstract ifrs-full:CashAndCashEquivalentsAbstract
276 Schedule of cash and cash equivalents Concept (Text Block (HTML)) For Period ktov:DisclosureOfDetailedInformationAboutCashAndCashEquivalentExplanatoryTableTextBlock
277 032 - Disclosure - Other Current Assets (Tables) Network

*

*

 http://kitovpharma.com/role/OtherCurrentAssetsTables
278 Implied Table Table

*

*

 implied:Table
279 Other Current Assets [Abstract] Abstract ktov:OtherCurrentAssetsAbstract
280 Schedule of other current assets Concept (Text Block (HTML)) For Period ktov:DisclosureOfDetailedInformationAboutOtherCcrrentAssetsExplanatoryTableTextBlock
281 033 - Disclosure - Other Payables (Tables) Network

*

*

 http://kitovpharma.com/role/OtherPayablesTables
282 Implied Table Table

*

*

 implied:Table
283 Other Payables [Abstract] Abstract ifrs-full:TradeAndOtherPayablesAbstract
284 Schedule of other payables Concept (Text Block (HTML)) For Period ktov:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock
285 034 - Disclosure - Equity (Tables) Network

*

*

 http://kitovpharma.com/role/EquityTables
286 Implied Table Table

*

*

 implied:Table
287 Equity [Abstract] Abstract ifrs-full:ChangesInEquityAbstract
288 Schedule of company's share capital Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory
289 Schedule of changes in share capital during the year Concept (Text Block (HTML)) For Period ktov:DisclosureOfDetailedInformationAboutChangesInShareCapitalExplanatoryTableTextBlock
290 Schedule of information relating to subsidiary that has material non-controlling interests Concept (Text Block (HTML)) For Period ktov:DisclosureOfDetailedInformationAboutNoncontrollingInterestsTableTextBlock
291 035 - Disclosure - Share-based Payment Arrangements (Tables) Network

*

*

 http://kitovpharma.com/role/SharebasedPaymentArrangementsTables
292 Disclosure of range of exercise prices of outstanding share options [table] Table

*

*

 ifrs-full:DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable
293 Option Indexed To Issuer Equity Type [Axis] Axis ktov:OptionIndexedToIssuerEquityTypeAxis
294 Option Indexed To Issuer Equity Type [Domain] Member ktov:OptionIndexedToIssuerEquityTypeDomain
295 Employee Stock Options [Member] Member ktov:EmployeeStockOptionsMember
296 Valuation techniques used in fair value measurement [axis] Axis ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis
297 Valuation techniques [member] Member ifrs-full:ValuationTechniquesMember
298 Binominal Model [Member] Member ifrs-full:OptionPricingModelMember
299 Disclosure of range of exercise prices of outstanding share options [line items] LineItems ifrs-full:DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems
300 Summary of number and weighted average exercise prices (in nis) of share options Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory
301 Summary of number of RSUs Concept (Text Block (HTML)) For Period ktov:DisclosureOfDetailedInformationAboutRestrictedStockUnitTableTextBlock
302 Summary of options to service providers were measured at the fair value of the service Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory
303 Summary of share based expenses Concept (Text Block (HTML)) For Period ktov:DisclosureOfDetailedInformationAboutSharebasedExpenseRecognizedExplanatoryTableTextBlock
304 036 - Disclosure - Transactions and Balances with Related Parties (Tables) Network

*

*

 http://kitovpharma.com/role/Transactionsandbalanceswithrelatedpartiestables
305 Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [table] Table

*

*

 ifrs-full:DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesTable
306 Categories of related parties [axis] Axis ifrs-full:CategoriesOfRelatedPartiesAxis
307 Entity's total for related parties [member] Member ifrs-full:EntitysTotalForRelatedPartiesMember
308 Executive Officers [Member] Member ktov:ChiefExecutivesOfficerMember
309 Directors [Member] Member ktov:DirectorsMember
310 Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items] LineItems ifrs-full:DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems
311 Schedule of payments to key management Concept (Text Block (HTML)) For Period ktov:DisclosureOfPaymentsToKeyManagementExplanatoryTableTextBlock
312 037 - Disclosure - Commitments and Contingent Liabilities (Tables) Network

*

*

 http://kitovpharma.com/role/CommitmentsandContingentLiabilitiesTables
313 Implied Table Table

*

*

 implied:Table
314 Commitments and Contingent Liabilities [Abstract] Abstract ifrs-full:DisclosureOfContingentLiabilitiesAbstract
315 Schedule of future minimum lease payments Concept (Text Block (HTML)) For Period ktov:DisclosureOfFutureMinimumLeasePaymentsTableTextBlock
316 038 - Disclosure - Research and Development Expenses (Tables) Network

*

*

 http://kitovpharma.com/role/ResearchandDevelopmentExpensesTables
317 Implied Table Table

*

*

 implied:Table
318 Research and Development Expenses [Abstract] Abstract ktov:ResearchAndDevelopmentExpensesAbstract
319 Schedule of research and development expenses Concept (Text Block (HTML)) For Period ktov:DisclosureOfResearchAndDevelopmentExpensesTableTextBlock
320 039 - Disclosure - General and Administrative Expenses (Tables) Network

*

*

 http://kitovpharma.com/role/GeneralAndAdministrativeExpensesTables
321 Implied Table Table

*

*

 implied:Table
322 General and Administrative Expenses [Abstract] Abstract ktov:GeneralAndAdministrativeExpensesAbstract
323 Schedule of of general and administrative expenses Concept (Text Block (HTML)) For Period ktov:DisclosureOfDetailedInformationAboutGeneralAndAdministrativeExpensesExplanatoryTableTextBlock
324 040 - Disclosure - Finance Expense (Income) (Tables) Network

*

*

 http://kitovpharma.com/role/FinanceExpenseIncomeTables
325 Implied Table Table

*

*

 implied:Table
326 Finance Expense (Income) [Abstract] Abstract ktov:FinanceExpenseIncomeAbstract
327 Schedule of net change in fair value of derivatives Concept (Text Block (HTML)) For Period ktov:DisclosureOfDetailedInformationAboutChangesInFairValueOfDerivativesExplanatoryTableTextBlock
328 Schedule of financing expenses (Income) Concept (Text Block (HTML)) For Period ktov:DisclosureOfDetailedInformationAboutFinanceIncomeExpenseExplanatoryTableTextBlock
329 041 - Disclosure - Employee Benefits (Tables) Network

*

*

 http://kitovpharma.com/role/EmployeebenefitsTables
330 Implied Table Table

*

*

 implied:Table
331 Employee Benefits [Abstract] Abstract ktov:EmployeeBenefitsAbstract
332 Schedule of post-employee benefits Concept (Text Block (HTML)) For Period ktov:DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock
333 Schedule of defined contribution plan in respect of its employees Concept (Text Block (HTML)) For Period ktov:DisclosureOfDetailedInformationAboutDefinedContributionPlanExplanatoryTableTextBlock
334 042 - Disclosure - Financial Instruments (Tables) Network

*

*

 http://kitovpharma.com/role/FinancialInstrumentsTables
335 Implied Table Table

*

*

 implied:Table
336 Financial Instruments [Abstract] Abstract ifrs-full:DisclosureOfFinancialInstrumentsAbstract
337 Schedule of sensitivity test to possible changes in USD/NIS exchange rate Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory
338 Schedule of financial instruments measured at fair value Concept (Text Block (HTML)) For Period ktov:ScheduleOfFinancialInstrumentsMeasuredAtFairValueTableTextBlock
339 Schedule of fair value measurement Concept (Text Block (HTML)) For Period ktov:ScheduleOfFairValueMeasurementAtLevelsTableTextBlock
340 043 - Disclosure - Significant Accounting Policies (Details) Network

*

*

 http://kitovpharma.com/role/SignificantAccountingPoliciesDetails
341 Implied Table Table

*

*

 implied:Table
342 Significant Accounting Policies [Abstract] Abstract ktov:SignificantAccountingPoliciesAbstract
343 Significant Accounting Policies (Textual) Abstract ktov:SignificantAccountingPoliciesTextualAbstract
344 Lease liability, description Concept (Text/String) For Period ifrs-full:DescriptionOfArrangementInvolvingLegalFormOfLease
345 Nominal discount rate used for measuring lease liability Concept (Percent) For Period ktov:NominalDiscountRateForMeasuringLeaseLiability
346 Lease liabilities Concept (Monetary) As Of Credit ifrs-full:LeaseLiabilities
347 044 - Disclosure - General (Details) Network

*

*

 http://kitovpharma.com/role/GeneralDetails
348 Disclosure of non-adjusting events after reporting period [table] Table

*

*

 ifrs-full:DisclosureOfNonadjustingEventsAfterReportingPeriodTable
349 Non-adjusting events after reporting period [axis] Axis ifrs-full:NonadjustingEventsAfterReportingPeriodAxis
350 Non-adjusting events after reporting period [member] Member ifrs-full:NonadjustingEventsMember
351 Announcement of plan to discontinue operation [member] Member ifrs-full:AnnouncementOfPlanToDiscontinueOperationMember
352 Disclosure of non-adjusting events after reporting period [line items] LineItems ifrs-full:DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems
353 Accumulated deficit Concept (Monetary) As Of Credit ifrs-full:RetainedEarnings
354 Fund raised for current development plans Concept (Monetary) For Period Debit ktov:PreliminaryExpenses
355 Description of warrants to purchase ADS Concept (Text/String) For Period ktov:DescriptionOfWarrantsToPurchaseAmericanDepositoryShares
356 045 - Disclosure - Basis of Preparation of the Financial Statements (Details) Network

*

*

 http://kitovpharma.com/role/BasisofPreparationoftheFinancialStatementsDetails
357 Foreign Exchange Rates [Table] Table

*

*

 ktov:ForeignExchangeRatesTable
358 Currency [Axis] Axis srt:CurrencyAxis
359 All Currencies [Domain] Member currency:AllCurrenciesDomain
360 Bank of Israel [Member] Member ktov:BankOfIsraelMember
361 Foreign Exchange Rates [Line Items] LineItems ktov:ForeignExchangeRatesLineItems
362 Representative exchange rate of USD (NIS/USD 1) Concept (Decimal) For Period ifrs-full:AverageForeignExchangeRate
363 Changes in exchange rates for the Year ended Concept (Percent) For Period ktov:ChangesInExchangeRates
364 046 - Disclosure - Basis of Preparation of the Financial Statements (Details 1) Network

*

*

 http://kitovpharma.com/role/BasisofPreparationoftheFinancialStatementsDetails1
365 Statement of changes in equity [table] Table

*

*

 ifrs-full:StatementOfChangesInEquityTable
366 Retrospective application and retrospective restatement [axis] Axis ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis
367 Previously stated [member] Member ifrs-full:PreviouslyStatedMember
368 According to IFRS 15 [Member] Member ktov:IncreaseDecreaseDueToChangesInIfrssMember
369 The change [Member] Member ktov:IncreaseDecreaseDueToVoluntaryChangesMember
370 According to the previous policy [Member] Member ktov:AccordingPreviouslyStatedMember
371 Statement of changes in equity [line items] LineItems ifrs-full:StatementOfChangesInEquityLineItems
372 Accumulated loss Concept (Monetary) As Of Credit ifrs-full:RetainedEarnings
373 Deferred income Concept (Monetary) As Of Credit ifrs-full:DeferredIncome
374 047 - Disclosure - Basis of Preparation of the Financial Statements (Details 2) Network

*

*

 http://kitovpharma.com/role/BasisofPreparationoftheFinancialStatementsDetails2
375 Statement of changes in equity [table] Table

*

*

 ifrs-full:StatementOfChangesInEquityTable
376 Retrospective application and retrospective restatement [axis] Axis ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis
377 Previously stated [member] Member ifrs-full:PreviouslyStatedMember
378 According to the previous policy [Member] Member ktov:AccordingPreviouslyStatedMember
379 The change [Member] Member ktov:IncreaseDecreaseDueToVoluntaryChangesMember
380 According to IFRS 15 [Member] Member ktov:IncreaseDecreaseDueToChangesInIfrssMember
381 Statement of changes in equity [line items] LineItems ifrs-full:StatementOfChangesInEquityLineItems
382 Revenues Concept (Monetary) For Period Credit ifrs-full:Revenue
383 General and administrative expenses Concept (Monetary) For Period Debit ifrs-full:GeneralAndAdministrativeExpense
384 Operating Loss Concept (Monetary) For Period Credit ifrs-full:ProfitLossFromOperatingActivities
385 Loss for the year Concept (Monetary) For Period Credit ifrs-full:ProfitLossFromContinuingOperations
386 Impact on basic and diluted loss per share data : Abstract ifrs-full:BasicEarningsPerShareAbstract
387 Basic and diluted loss per share - USD Concept (Share) For Period ifrs-full:BasicAndDilutedEarningsLossPerShare
388 048 - Disclosure - Basis of Preparation of the Financial Statements (Details Textual) Network

*

*

 http://kitovpharma.com/role/BasisofPreparationoftheFinancialStatementsDetails3
389 Statement of changes in equity [table] Table

*

*

 ifrs-full:StatementOfChangesInEquityTable
390 Retrospective application and retrospective restatement [axis] Axis ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis
391 Previously stated [member] Member ifrs-full:PreviouslyStatedMember
392 According to IFRS 15 [Member] Member ktov:IncreaseDecreaseDueToChangesInIfrssMember
393 The change [Member] Member ktov:IncreaseDecreaseDueToVoluntaryChangesMember
394 Statement of changes in equity [line items] LineItems ifrs-full:StatementOfChangesInEquityLineItems
395 Deferred revenue Concept (Monetary) For Period Credit ifrs-full:Revenue
396 Net of costs Concept (Monetary) For Period Debit ifrs-full:GeneralAndAdministrativeExpense
397 Retained earnings Concept (Monetary) As Of Credit ifrs-full:RetainedEarnings
398 049 - Disclosure - Operating Segments (Details) Network

*

*

 http://kitovpharma.com/role/OperatingSegmentsDetails
399 Financial Information By Operating Segments [Table] Table

*

*

 ktov:FinancialInformationByOperatingSegmentsTable
400 Segments [axis] Axis ifrs-full:SegmentsAxis
401 Segments [member] Member ifrs-full:SegmentsMember
402 Pain And Hypertension [Member] Member ktov:PainAndHypertensionMember
403 Oncology [Member] Member ktov:OncologyMember
404 Total Reportable Segments [Member] Member ktov:TotalReportableSegmentsMember
405 Reconciliations [Member] Member ktov:ReconciliationsMember
406 Disclosure of disaggregation of revenue from contracts with customers [line items] LineItems ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems
407 Revenues Concept (Monetary) For Period Credit ifrs-full:Revenue
408 Research and development expenses Concept (Monetary) For Period Debit ifrs-full:ResearchAndDevelopmentExpense
409 Operating Loss Concept (Monetary) For Period Credit ifrs-full:ProfitLossFromOperatingActivities
410 Finance income, net Concept (Monetary) For Period Debit ktov:FinanceExpensesNet
411 Loss for the year Concept (Monetary) For Period Credit ifrs-full:ProfitLossFromContinuingOperations
412 050 - Disclosure - Operating Segments (Details Textual) Network

*

*

 http://kitovpharma.com/role/OperatingSegmentsDetailsTextual
413 Implied Table Table

*

*

 implied:Table
414 Operating Segments [Abstract] Abstract ifrs-full:DisclosureOfOperatingSegmentsAbstract
415 Number of reportable segments Concept (Integer) For Period ktov:NumberOfReportableSegment
416 Number of customers Concept (Integer) As Of ktov:NumberOfCustomers
417 051 - Disclosure - Subsidiary (Details) Network

*

*

 http://kitovpharma.com/role/Acquisitionofsubsidiarydetails
418 Implied Table Table

*

*

 implied:Table
419 Subsidiary [Abstract] Abstract ktov:SubsidiariesAbstract
420 Summary of acquisition date fair value of each major class of consideration: Abstract ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferredAbstract
421 Cash Concept (Monetary) As Of Credit ifrs-full:CashTransferred
422 Equity instruments issued (564,625 Ordinary Shares) (1) Concept (Monetary) As Of Credit ifrs-full:EquityInterestsOfAcquirer
423 Assignment of loan to the Company Concept (Monetary) As Of Credit ifrs-full:LiabilitiesIncurred
424 Total consideration transferred Concept (Monetary) As Of Credit ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred
425 052 - Disclosure - Subsidiary (Details 1) Network

*

*

 http://kitovpharma.com/role/AcquisitionOfSubsidiarydetails1
426 Implied Table Table

*

*

 implied:Table
427 Subsidiary [Abstract] Abstract ktov:SubsidiariesAbstract
428 Summary of recognized amounts of assets acquired and liabilities assumed at the date of acquisition: Abstract ifrs-full:AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract
429 Current assets Concept (Monetary) As Of Debit ifrs-full:CurrentAssetsRecognisedAsOfAcquisitionDate
430 Fixed assets, net Concept (Monetary) As Of Debit ifrs-full:FinancialAssetsRecognisedAsOfAcquisitionDate
431 Intangible assets Concept (Monetary) As Of Debit ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate
432 Short-term credit from bank Concept (Monetary) As Of Credit ifrs-full:BorrowingsRecognisedAsOfAcquisitionDate
433 Trade payables Concept (Monetary) As Of Credit ktov:TradePayablesRecognisedAsOfAcquisitionDate
434 Other payables Concept (Monetary) As Of Credit ktov:OtherPayablesRecognisedAsOfAcquisitionDate
435 Long-term related parties Concept (Monetary) As Of Credit ifrs-full:NoncurrentLiabilitiesRecognisedAsOfAcquisitionDate
436 Total net identifiable assets Concept (Monetary) As Of Debit ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed
437 053 - Disclosure - Subsidiaries (Details 2) Network

*

*

 http://kitovpharma.com/role/SubsidiariesDetails
438 Disclosure of subsidiaries [table] Table

*

*

 ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesTable
439 Categories of related parties [axis] Axis ifrs-full:CategoriesOfRelatedPartiesAxis
440 Entity's total for related parties [member] Member ifrs-full:EntitysTotalForRelatedPartiesMember
441 Group's [Member] Member ktov:GroupMember
442 Group One [Member] Member ktov:GroupOneMember
443 Kitov Pharmaceuticals Ltd. [Member] Member ktov:KitovMember
444 TyrNovo Ltd [Member] Member ktov:TyrNovoLtdMember
445 Classes of acquired receivables [axis] Axis ifrs-full:ClassesOfAcquiredReceivablesAxis
446 Classes of acquired receivables [member] Member ifrs-full:ClassesOfAcquiredReceivablesMember
447 Loans [member] Member ifrs-full:LoansAcquiredInBusinessCombinationMember
448 Continuing involvement in derecognised financial assets by type of instrument [axis] Axis ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis
449 Types of instrument [member] Member ifrs-full:TypesOfInstrumentMember
450 Guarantees [member] Member ifrs-full:GuaranteesMember
451 Subsidiaries [axis] Axis ifrs-full:SignificantInvestmentsInSubsidiariesAxis
452 Entity's total for subsidiaries [member] Member ifrs-full:EntitysTotalForSubsidiariesMember
453 Subsidiary [member] Member ifrs-full:SubsidiariesMember
454 Disclosure of subsidiaries [line items] LineItems ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesLineItems
455 Name of subsidiary Concept (Text/String) For Period ifrs-full:NameOfSubsidiary
456 Country of incorporation of subsidiary Concept (Text/String) For Period ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary
457 Group's ownership equity Concept (Percent) For Period ktov:ProportionOfGroupOwnershipInterestInSubsidiary
458 Company's direct ownership of equity Concept (Percent) For Period ifrs-full:ProportionOfOwnershipInterestInSubsidiary
459 Amounts provided by the Company to the subsidiary Loan Concept (Monetary) As Of Credit ifrs-full:LoansReceived
460 Amounts provided by the Company to the subsidiary Guarantees Concept (Monetary) As Of Credit ktov:GuaranteesAmount
461 Total investment in subsidiary Concept (Monetary) As Of Debit ifrs-full:InvestmentProperty
462 054 - Disclosure - Subsidiary (Details Textual) Network

*

*

 http://kitovpharma.com/role/AcquisitionOfSubsidiarydetailstextual
463 Disclosure of detailed information about business combination [table] Table

*

*

 ifrs-full:DisclosureOfBusinessCombinationsTable
464 Name Of Acquiree [Axis] Axis ktov:NameOfAcquireeAxis
465 Name Of Acquiree [Domain] Member ktov:NameOfAcquireeDomain
466 GHP [Member] Member ktov:GoldmanHirshPartnersLtdMember
467 Categories of related parties [axis] Axis ifrs-full:CategoriesOfRelatedPartiesAxis
468 Entity's total for related parties [member] Member ifrs-full:EntitysTotalForRelatedPartiesMember
469 TyrNovo [Member] Member ktov:TyrNovoLtdMember
470 Kitov [Member] Member ktov:KitovMember
471 Taoz [Member] Member ktov:TaozMember
472 Components of equity [axis] Axis ifrs-full:ComponentsOfEquityAxis
473 Equity [member] Member ifrs-full:EquityMember
474 ADS [Member] Member ktov:AdsMember
475 Disclosure of detailed information about business combination [line items] LineItems ifrs-full:DisclosureOfBusinessCombinationsLineItems
476 Subsidiary (Textual) Abstract ktov:SubsidiaryTextualAbstract
477 Cash proceeds Concept (Monetary) As Of Credit ifrs-full:CashTransferred
478 Percentage of ordinary shares acquired Concept (Percent) As Of ifrs-full:PercentageOfVotingEquityInterestsAcquired
479 Ordinary shares issued Concept (Shares) As Of ktov:BusinessAcquisitionEquityInterestIssuedOrIssuableNumberOfSharesIssued
480 Loans Concept (Monetary) As Of Credit ifrs-full:LoansPayableInDefault
481 Cash consideration paid Concept (Monetary) For Period Credit ifrs-full:ConsiderationPaidReceived
482 Contributed losses Concept (Monetary) For Period Debit ktov:ContributedLosses
483 Fair value of ordinary shares issued price per share Concept (Share) As Of ktov:BusinessAcquisitionEquityInterestIssuedOrIssuablePricePerShare
484 Liquidated damages, description Concept (Text/String) For Period ktov:DescriptionOfLiquidatedDamages
485 055 - Disclosure - Subsidiary (Details Textual 1) Network

*

*

 http://kitovpharma.com/role/SubsidiaryDetailsTextual1
486 Implied Table Table

*

*

 implied:Table
487 Subsidiary [Abstract] Abstract ktov:SubsidiariesAbstract
488 Name of acquiree Concept (Text/String) For Period ifrs-full:NameOfAcquiree
489 Description of acquiree Concept (Text/String) For Period ifrs-full:DescriptionOfAcquiree
490 Number of share issued Concept (Decimal) As Of ifrs-full:NumberOfInstrumentsOrInterestsIssuedOrIssuable
491 Measurement of issued and outstanding share capital, description Concept (Text/String) For Period ifrs-full:MethodOfDeterminingFairValueOfInstrumentsOrInterests
492 Description of measurement basis for non-controlling interest in acquiree recognised at acquisition date Concept (Text/String) For Period ifrs-full:DescriptionOfMeasurementBasisForNoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate
493 Option granted Concept (Monetary) As Of Credit ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted
494 Description of option pricing Concept (Text/String) For Period ifrs-full:DescriptionOfOptionPricingModelShareOptionsGranted
495 Percentage of voting equity interests acquired Concept (Percent) As Of ifrs-full:PercentageOfVotingEquityInterestsAcquired
496 Provided to Taoz a put option to sell, description Concept (Text/String) For Period ifrs-full:DescriptionOfInputsToOptionPricingModelShareOptionsGranted
497 Rights granted, share options granted Concept (Monetary) For Period ifrs-full:ExercisePriceShareOptionsGranted
498 other expenses Concept (Monetary) For Period Debit ifrs-full:OtherExpenseByNature
499 Finance expense Concept (Monetary) For Period Debit ifrs-full:FinanceCosts
500 Price per share Concept (Share) As Of ifrs-full:ParValuePerShare
501 056 - Disclosure - Subsidiary (Details Textual 2) Network

*

*

 http://kitovpharma.com/role/SubsidiaryDetails4
502 Disclosure of detailed information about business combination [table] Table

*

*

 ifrs-full:DisclosureOfBusinessCombinationsTable
503 Components of equity [axis] Axis ifrs-full:ComponentsOfEquityAxis
504 Equity [member] Member ifrs-full:EquityMember
505 ADS [Member] Member ktov:AdsMember
506 Categories of related parties [axis] Axis ifrs-full:CategoriesOfRelatedPartiesAxis
507 Entity's total for related parties [member] Member ifrs-full:EntitysTotalForRelatedPartiesMember
508 Taoz [Member] Member ktov:TaozMember
509 Disclosure of detailed information about business combination [line items] LineItems ifrs-full:DisclosureOfBusinessCombinationsLineItems
510 Subsidiary Textual [Abstract] Abstract ktov:SubsidiaryTextualAbstract
511 Acquisition of additional stake percentage Concept (Percent) As Of ktov:AcquisitionOfAdditionalStakePercentage
512 Percentage of ordinary shares acquired Concept (Percent) As Of ifrs-full:PercentageOfVotingEquityInterestsAcquired
513 Held in ordinary shares Concept (Shares) For Period ktov:OrdinarySharesHeld
514 Percentage of issued and outstanding share capital Concept (Percent) For Period ktov:PercentageOfIssuedAndOutstandingShareCapital
515 Ordinary shares issued Concept (Shares) As Of ktov:BusinessAcquisitionEquityInterestIssuedOrIssuableNumberOfSharesIssued
516 Carrying amount of net assets on date of the acquisition Concept (Monetary) As Of Debit ktov:NetAssetsRecognisedAsOfAcquisitionDate
517 Decrease in non-controlling interests Concept (Monetary) For Period Credit ktov:IncreaseDecreaseInNoncontrollingInterests
518 Increase in share premium Concept (Monetary) For Period Credit ktov:IncreaseDecreaseInSharePremium
519 Decrease in a capital reserve for transactions with non-controlling interest Concept (Monetary) For Period Credit ktov:IncreaseDecreaseInCapitalReserveForTransactionsWithNoncontrollingInterest
520 Percentage of issued and outstanding ordinary shares Concept (Percent) For Period ktov:PercentageOfIssuedAndOutstandingOrdinaryShares
521 Fair value of the shares issued in consideration for waving the rights amount Concept (Monetary) For Period Credit ktov:FairValueOfSharesIssuedInConsiderationForWavingRightsAmount
522 Derivative financial liabilities Concept (Monetary) As Of Credit ifrs-full:DerivativeFinancialLiabilities
523 Other income Concept (Monetary) For Period Credit ifrs-full:OtherIncome
524 Increase in share premium deriving from the waiving of the rights Concept (Monetary) For Period Debit ktov:IncreaseInSharePremiumDerivingFromWaivingOfRights
525 Finance expense Concept (Monetary) For Period Debit ifrs-full:FinanceCosts
526 057 - Disclosure - Cash and Cash Equivalents (Details) Network

*

*

 http://kitovpharma.com/role/CashandCashEquivalentsDetails
527 Disclosure Of Cash And Cash Equivalents [Table] Table

*

*

 ktov:DisclosureOfCashAndCashEquivalentsTable
528 Currency [Axis] Axis srt:CurrencyAxis
529 All Currencies [Domain] Member currency:AllCurrenciesDomain
530 Balance in USD [Member] Member ktov:UsdMember
531 Balance in other currencies [Member] Member ktov:OtherCurenciesMember
532 Disclosure Of Cash And Cash Equivalents [Line Items] LineItems ktov:DisclosureOfCashAndCashEquivalentsLineItems
533 Total cash and cash equivalents Concept (Monetary) As Of Debit ifrs-full:CashAndCashEquivalents
534 058 - Disclosure - Other Current Assets (Details) Network

*

*

 http://kitovpharma.com/role/OtherCurrentAssetsDetails
535 Implied Table Table

*

*

 implied:Table
536 Other Current Assets [Abstract] Abstract ktov:OtherCurrentAssetsAbstract
537 Government authorities Concept (Monetary) As Of Debit ktov:GovernmentAuthorities
538 Reimbursement of legal fees receivable Concept (Monetary) As Of Debit ktov:ReimbursementOfLegalFeesReceivable
539 Prepaid fee to the Food and Drug Administration Concept (Monetary) As Of Debit ktov:PrepaidFeeToTheFoodAndDrugAdministration
540 Prepaid expenses and other receivables Concept (Monetary) As Of Debit ktov:PrepaidExpensesAndOtherReceivables
541 Total other current assets Concept (Monetary) As Of Debit ifrs-full:OtherCurrentAssets
542 059 - Disclosure - Other Current Assets (Details Textual) Network

*

*

 http://kitovpharma.com/role/OtherCurrentAssetsDetailsTextual
543 Implied Table Table

*

*

 implied:Table
544 Other Current Assets [Abstract] Abstract ktov:OtherCurrentAssetsAbstract
545 Other Current Assets (Textual) Abstract ktov:OtherCurrentAssetsTextualAbstract
546 Deposits Concept (Monetary) As Of Credit ktov:DepositLiabilities
547 060 - Disclosure - Other Payables (Details) Network

*

*

 http://kitovpharma.com/role/OtherPayablesDetails
548 Implied Table Table

*

*

 implied:Table
549 Other Payables [Abstract] Abstract ifrs-full:TradeAndOtherPayablesAbstract
550 Due to related parties - payroll related Concept (Monetary) As Of Credit ifrs-full:TradeAndOtherPayablesToRelatedParties
551 Due to GHP (Note 5A) Concept (Monetary) As Of Credit ktov:CurrentPayablesToOtherRelatedParties
552 Accrued expenses Concept (Monetary) As Of Credit ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities
553 Government authorities Concept (Monetary) As Of Credit ktov:PayableToGovernmentAuthoritiesCurrent
554 Payroll related payables Concept (Monetary) As Of Credit ktov:PayrollRelatedPayables
555 Deferred income Concept (Monetary) As Of Credit ifrs-full:DeferredIncomeClassifiedAsCurrent
556 Other Payables Total Concept (Monetary) As Of Credit ifrs-full:OtherCurrentPayables
557 061 - Disclosure - Equity (Details) Network

*

*

 http://kitovpharma.com/role/EquityDetails
558 Disclosure of classes of share capital [table] Table

*

*

 ifrs-full:DisclosureOfClassesOfShareCapitalTable
559 Classes Of Preferred Shares [Axis] Axis ktov:ClassesOfPreferredSharesAxis
560 Classes Of Preferred Shares [Domain] Member ktov:ClassesOfPreferredSharesDomain
561 Class A preferred shares [Member] Member ktov:PreferredShareClassMember
562 Class B preferred shares [Member] Member ktov:PreferredShareClassBMember
563 Class C preferred shares [Member] Member ktov:PreferredClassCMember
564 Class D preferred share [Member] Member ktov:PreferredClassDMember
565 Class E preferred shares [Member] Member ktov:PreferredClassEMember
566 Classes of ordinary shares [axis] Axis ifrs-full:ClassesOfOrdinarySharesAxis
567 Ordinary shares [member] Member ifrs-full:OrdinarySharesMember
568 Ordinary shares [Member] Member ktov:OrdinaryShareMember
569 Disclosure of classes of share capital [line items] LineItems ifrs-full:DisclosureOfClassesOfShareCapitalLineItems
570 Number of shares, Authorized Concept (Shares) As Of ifrs-full:NumberOfSharesAuthorised
571 Number of shares, Issued and paid-in Concept (Shares) As Of ifrs-full:NumberOfSharesIssuedAndFullyPaid
572 062 - Disclosure - Equity (Details 1) Network

*

*

 http://kitovpharma.com/role/EquityDetails1
573 Implied Table Table

*

*

 implied:Table
574 Equity [Abstract] Abstract ifrs-full:ChangesInEquityAbstract
575 Issued as at January 1 Concept (Shares) As Of ifrs-full:NumberOfSharesIssued
576 Issuance of ADSs (See D below) Concept (Shares) For Period ktov:NumberOfIssuanceOfAdsShares
577 Issuance of shares (See Note 5) Concept (Shares) For Period ktov:NumberOfIssuanceShares
578 Share issuance deriving from a development agreement (See E6 below) Concept (Shares) For Period ktov:NumberOfSharesIssuanceDerivingFromStrategicCooperationAgreement
579 Share based payments Concept (Shares) For Period ktov:NumberOfShareBasedPayments
580 Exercise of warrants Concept (Shares) For Period ktov:NumberOfExerciseOfWarrants
581 Issued as at December 31 Concept (Shares) As Of ifrs-full:NumberOfSharesIssued
582 063 - Disclosure - Equity (Details 2) Network

*

*

 http://kitovpharma.com/role/Equitydetails2
583 Noncontrolling Interests [Table] Table

*

*

 ktov:NoncontrollingInterestsTable
584 Components of equity [axis] Axis ifrs-full:ComponentsOfEquityAxis
585 Equity [member] Member ifrs-full:EquityMember
586 Non-controlling interests [member] Member ifrs-full:NoncontrollingInterestsMember
587 Categories of related parties [axis] Axis ifrs-full:CategoriesOfRelatedPartiesAxis
588 Entity's total for related parties [member] Member ifrs-full:EntitysTotalForRelatedPartiesMember
589 TyrNovo Ltd. [Member] Member ktov:TyrNovoLtdMember
590 Noncontrolling Interests [Line Items] LineItems ktov:NoncontrollingInterestsLineItems
591 Non-controlling interests percentage Concept (Percent) For Period ifrs-full:ProportionOfOwnershipInterestsHeldByNoncontrollingInterests
592 Non-current assets Concept (Monetary) As Of Debit ifrs-full:NoncurrentAssets
593 Current assets Concept (Monetary) As Of Debit ifrs-full:CurrentAssets
594 Current liabilities Concept (Monetary) As Of Credit ifrs-full:CurrentLiabilities
595 Net assets Concept (Monetary) As Of Debit ifrs-full:NetAssetsLiabilities
596 Net assets attributable to non-controlling interests Concept (Monetary) As Of Debit ktov:NetAssetsAttributableToNoncontrollingInterests
597 Loss for the year Concept (Monetary) For Period Credit ifrs-full:ProfitLossFromContinuingOperationsAttributableToNoncontrollingInterests
598 Loss allocated to non-controlling interests Concept (Monetary) For Period Credit ifrs-full:ProfitLossAttributableToNoncontrollingInterests
599 064 - Disclosure - Equity (Details Textual) Network

*

*

 http://kitovpharma.com/role/Equitydetailstextual
600 Disclosure of classes of share capital [table] Table

*

*

 ifrs-full:DisclosureOfClassesOfShareCapitalTable
601 Components of equity [axis] Axis ifrs-full:ComponentsOfEquityAxis
602 Equity [member] Member ifrs-full:EquityMember
603 Direct Offering [Member] Member ktov:DirectOfferingMember
604 Public Offering [Member] Member ktov:PublicOfferingMember
605 ADS [Member] Member ktov:AdsMember
606 NASDAQ [Member] Member ktov:NasdaqMember
607 Auction Market Preferred Security Stock Series [Axis] Axis ktov:AuctionMarketPreferredSecurityStockSeriesAxis
608 Auction Market Preferred Securities Stock Series [Domain] Member ktov:AuctionMarketPreferredSecuritiesStockSeriesDomain
609 Series A warrant [Member] Member ktov:SeriesWarrantMember
610 Series B warrant [Member] Member ktov:SeriesBWarrantMember
611 Classes Of Units [Axis] Axis ktov:ClassesOfUnitsAxis
612 Classes Of Units [Domain] Member ktov:ClassesOfUnitsDomain
613 Class A units [Member] Member ktov:ClassUnitsMember
614 Class B units [Member] Member ktov:ClassBUnitsMember
615 Categories of related parties [axis] Axis ifrs-full:CategoriesOfRelatedPartiesAxis
616 Entity's total for related parties [member] Member ifrs-full:EntitysTotalForRelatedPartiesMember
617 Dexcel Ltd. [Member] Member ifrs-full:JointControlOrSignificantInfluenceMember
618 Classes of ordinary shares [axis] Axis ifrs-full:ClassesOfOrdinarySharesAxis
619 Ordinary shares [member] Member ifrs-full:OrdinarySharesMember
620 Ordinary share [Member] Member ktov:OrdinaryShareMember
621 Disclosure of classes of share capital [line items] LineItems ifrs-full:DisclosureOfClassesOfShareCapitalLineItems
622 Company funds raised Concept (Monetary) As Of Debit ktov:FundsRaisedAmount
623 Placement agent fees and other offering related expenses Concept (Monetary) For Period Debit ifrs-full:ProfessionalFeesExpense
624 Public offering issued by securities Concept (Shares) For Period ktov:StockIssuedDuringPeriodSharesIssues
625 Concurrent private placement issued Concept (Shares) For Period ktov:NumberOfConcurrentPrivatePlacementIssued
626 Public offering price Concept (Share) As Of ktov:PriceOfShare
627 Public offering price per unit Concept (Share) As Of ifrs-full:ParValuePerShare
628 Exercise price Concept (Share) For Period ktov:ExercisePriceOfOutstandingPerShareOptions
629 Warrant exercise price Concept (Share) For Period ktov:InvestmentWarrantExercisePrice
630 Warrants to purchase shares of common stock Concept (Shares) For Period ktov:PurchaseOfCommonStockAndWarrants
631 Deduction of underwrters commisions Concept (Monetary) For Period Debit ifrs-full:ReceiptsFromRoyaltiesFeesCommissionsAndOtherRevenue
632 Term of warrants Concept (xbrli:durationItemType) For Period ktov:WarrantsTerm
633 Adjusted value of warrants Concept (Monetary) For Period Credit ktov:AdjustedValueOfWarrants
634 Description of warrants rights Concept (Text/String) For Period ktov:ClassOfWarrantsOrRightTitleOfSecurityWarrantsOrRightsOutstanding
635 Shares to service providers for services granted Concept (Shares) For Period ktov:StockIssuedForServices
636 Shares to service providers for services granted, value Concept (Monetary) For Period Credit ktov:ValueIssuedForServices
637 Proceeds from exercise of warrants Concept (Monetary) For Period Debit ifrs-full:ProceedsFromExerciseOfOptions
638 General and administrative expenses Concept (Monetary) For Period Debit ifrs-full:AdministrativeExpense
639 Deferred prepaid expenses Concept (Monetary) For Period Debit ktov:DeferredPrepaidExpenses
640 Non-listed warrants Concept (Shares) For Period ktov:NonListedWarrants
641 Company issued securities, description Concept (Text/String) For Period ktov:IssuedSecuritiesPublicOfferingDescription
642 Issue of equity Concept (Monetary) For Period Credit ifrs-full:IssueOfEquity
643 Finance expenses Concept (Monetary) For Period Credit ktov:FinanceExpenses
644 Ordinary shares of vested restricted stock units Concept (Shares) For Period ktov:OrdinarySharesOfVestedRestrictedStockUnits
645 Ordinary shares restricted stock units Concept (Monetary) For Period Debit ktov:OrdinarySharesRestrictedStockUnits
646 065 - Disclosure - Share-based Payment Arrangements (Details) Network

*

*

 http://kitovpharma.com/role/SharebasedPaymentArrangementsDetails
647 Disclosure of terms and conditions of share-based payment arrangement [table] Table

*

*

 ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable
648 Continuing involvement in derecognised financial assets by type of instrument [axis] Axis ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis
649 Types of instrument [member] Member ifrs-full:TypesOfInstrumentMember
650 Currency [Axis] Axis srt:CurrencyAxis
651 All Currencies [Domain] Member currency:AllCurrenciesDomain
652 Bank of Israel [Member] Member ktov:BankOfIsraelMember
653 NIS [Member] Member ktov:NisMember
654 Disclosure of terms and conditions of share-based payment arrangement [line items] LineItems ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems
655 Weighted average exercise prices (in USD) Abstract ktov:WeightedAverageExercisePriceAbstract
656 Outstanding at January 1 Concept (Share) As Of ktov:WeightedAverageExercisePriceOfShareOptionOutstandingInSharebasedPaymentArrangement
657 Expired during the year Concept (Share) For Period ktov:WeightedAverageExercisePriceOfShareOptionExpiredInSharebasedPaymentArrangement
658 Granted during the year Concept (Share) For Period ktov:WeightedAverageExercisePriceOfShareOptionGrantedInSharebasedPaymentArrangement
659 Outstanding at December 31 Concept (Share) As Of ktov:WeightedAverageExercisePriceOfShareOptionOutstandingInSharebasedPaymentArrangement
660 Exercisable at December 31 Concept (Share) As Of ktov:WeightedAverageExercisePriceOfShareOptionExercisableInSharebasedPaymentArrangement
661 Number of options Abstract ktov:NumberOfOptionsAbstract
662 Outstanding at January 1 Concept (Shares) As Of ktov:NumberOfOutstandingShareOption
663 Expired during the year Concept (Shares) For Period ktov:NumberOfShareOptionExpiredInSharebasedPaymentArrangement
664 Granted during the year Concept (Shares) For Period ktov:NumberOfShareOptionGrantedInSharebasedPaymentArrangement
665 Outstanding at December 31 Concept (Shares) As Of ktov:NumberOfOutstandingShareOption
666 Exercisable at December 31 Concept (Shares) As Of ktov:NumberOfShareOptionExercisableInSharebasedPaymentArrangement
667 066 - Disclosure - Share-based Payment Arrangements (Details 1) Network

*

*

 http://kitovpharma.com/role/ShareBasedPaymentArrangementsDetails1
668 Implied Table Table

*

*

 implied:Table
669 Share-based Payment Arrangements [Abstract] Abstract ktov:ShareBasedPaymentArrangementsAbstract
670 Number of RSUs Abstract ktov:NumberOfRestrictedStockUnitsAbstract
671 Outstanding at January 1 Concept (Shares) As Of ktov:ShareBasedPaymentArrangementsOutstandingRestrictedStockUnits
672 Granted during the year Concept (Shares) For Period ktov:ShareBasedPaymentArrangementsRestrictedStockUnitsGranted
673 Vested during the year Concept (Shares) For Period ktov:ShareBasedPaymentArrangementsRestrictedStockUnitsVested
674 Outstanding at December 31 Concept (Shares) As Of ktov:ShareBasedPaymentArrangementsOutstandingRestrictedStockUnits
675 067 - Disclosure - Share-based Payment Arrangements (Details 2) Network

*

*

 http://kitovpharma.com/role/ShareBasedPaymentArrangementsDetails2
676 Disclosure of range of exercise prices of outstanding share options [table] Table

*

*

 ifrs-full:DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable
677 Ranges [Axis] Axis ktov:RangesAxis
678 Ranges [Domain] Member ktov:RangesDomain
679 Minimum [member] Member ifrs-full:BottomOfRangeMember
680 Maximum [member] Member ifrs-full:TopOfRangeMember
681 Valuation techniques used in fair value measurement [axis] Axis ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis
682 Valuation techniques [member] Member ifrs-full:ValuationTechniquesMember
683 Binominal Model [Member] Member ifrs-full:OptionPricingModelMember
684 Disclosure of range of exercise prices of outstanding share options [line items] LineItems ifrs-full:DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems
685 Share Price - USD Concept (Share) As Of ktov:DescriptionOfSharePriceShareOptionsGranted
686 Option price - USD Concept (Share) As Of ktov:DescriptionOfOptionPriceShareOptionsGranted
687 Expected volatility (%) Concept (Percent) For Period ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
688 Expected duration (years) Concept (xbrli:durationItemType) For Period ktov:DescriptionOfExpectedTermShareOptionsGranted
689 Dividend yield (%) Concept (Percent) For Period ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
690 Risk free rate interest rate (%) Concept (Percent) For Period ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
691 068 - Disclosure - Share-based Payment Arrangements (Details 3) Network

*

*

 http://kitovpharma.com/role/ShareBasedPaymentArrangementsDetails3
692 Implied Table Table

*

*

 implied:Table
693 Share-based Payment Arrangements [Abstract] Abstract ktov:ShareBasedPaymentArrangementsAbstract
694 Research and development expenses Concept (Monetary) For Period Debit ifrs-full:ResearchAndDevelopmentExpense
695 General and administrative expenses Concept (Monetary) For Period Debit ifrs-full:GeneralAndAdministrativeExpense
696 Other expenses Concept (Monetary) For Period Debit ifrs-full:OtherExpenseByNature
697 Total share-based expense recognized Concept (Monetary) For Period Debit ifrs-full:AdjustmentsForSharebasedPayments
698 069 - Disclosure - Share-based Payment Arrangements (Details Textual) Network

*

*

 http://kitovpharma.com/role/ShareBasedPaymentArrangementsDetailsTextual
699 Disclosure of terms and conditions of share-based payment arrangement [table] Table

*

*

 ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable
700 Categories of related parties [axis] Axis ifrs-full:CategoriesOfRelatedPartiesAxis
701 Entity's total for related parties [member] Member ifrs-full:EntitysTotalForRelatedPartiesMember
702 Board of Directors [Member] Member ktov:BoardOfDirectorsMember
703 Directors [Member] Member ktov:DirectorsMember
704 Two Consultants [Member] Member ktov:TwoConsultantsMember
705 Chairman of Board of Directors [Member] Member ktov:ChairmanOfBoardOfDirectorsMember
706 Service Provider [Member] Member ktov:ServiceProviderMember
707 Directors and Officers [Member] Member ktov:DirectorsAndOfficersMember
708 Chief Executives Officer [Member] Member ktov:ChiefExecutivesOfficerMember
709 Chief Financials Officer [Member] Member ktov:ChiefFinancialsOfficerMember
710 Senior Employees [Member] Member ktov:SeniorEmployeesMember
711 Offeree [Member] Member ktov:OffereeMember
712 Two Executives [Member] Member ktov:TwoExecutivesMember
713 TyrNovo [Member] Member ktov:TyrnovoMember
714 Continuing involvement in derecognised financial assets by type of instrument [axis] Axis ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis
715 Types of instrument [member] Member ifrs-full:TypesOfInstrumentMember
716 Options [Member] Member ktov:OptionsMember
717 Award [Axis] Axis ktov:AwardAxis
718 Award [Domain] Member ktov:AwardDomain
719 RSUs [Member] Member ktov:RsuMember
720 Types of share-based payment arrangements [axis] Axis ifrs-full:TypesOfSharebasedPaymentArrangementsAxis
721 Share-based payment arrangements [member] Member ifrs-full:SharebasedPaymentArrangementsMember
722 Share Based Payment Arrangement [Member] Member ktov:ShareBasedPaymentArrangementMember
723 Creation date [axis] Axis ifrs-full:CreationDateAxis
724 Default financial statements date [member] Member ifrs-full:DefaultFinancialStatementsDateMember
725 November 25, 2015 [Member] Member ktov:NovemberTwentyFiveTwoZeroOneFiveMember
726 May 22, 2016 [Member] Member ktov:MayTwentyTwoTwoZeroOneFiveMember
727 Ranges [Axis] Axis ktov:RangesAxis
728 Ranges [Domain] Member ktov:RangesDomain
729 Top of range [member] Member ifrs-full:TopOfRangeMember
730 Bottom of range [member] Member ifrs-full:BottomOfRangeMember
731 Disclosure of terms and conditions of share-based payment arrangement [line items] LineItems ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems
732 Number of shares approved Concept (Shares) As Of ifrs-full:NumberOfSharesIssued
733 Vesting period Concept (xbrli:durationItemType) For Period ktov:VestingPeriod
734 Exercise period Concept (xbrli:durationItemType) For Period ktov:ExercisePeriod
735 Number of options exercisable into shares Concept (Shares) For Period ktov:NumberOfShareOptionsExercisableIntoOrdinaryShares
736 Key management personnel Concept (Monetary) For Period Debit ifrs-full:KeyManagementPersonnelCompensation
737 Fair value expense Concept (Monetary) For Period Debit ktov:FairValueExpense
738 Description of options exercise term Concept (Text/String) For Period ktov:DescriptionOfShareOptionsExercisableInSharebasedPaymentArrangement
739 Options exercise price Concept (Share) For Period ktov:WeightedAverageExercisePriceOfShareOptionsVestingInPeriodSharebasedPaymentArrangement
740 Fully vested grant Concept (Shares) For Period ktov:FullyVestedGrant
741 Fair value of options and grants measured Concept (Monetary) For Period Debit ktov:FairValueOfOptionsAndGrantsMeasured
742 Additional ordinary shares Concept (Shares) For Period ktov:AdditionalOrdinaryShares
743 Number of additional options granted Concept (Shares) For Period ktov:NumberOfAdditionalOptionsGranted
744 Number of grant option shares Concept (Shares) For Period ktov:NumberOfShareOptionsGranted
745 Term of vesting share options Concept (xbrli:durationItemType) For Period ktov:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriods
746 Additional number of shares issued Concept (Shares) As Of ktov:AdditionalNumberOfSharesIssued
747 Weighted average exercise price Concept (Share) For Period ktov:ShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
748 Weighted average remaining contractual life Concept (xbrli:durationItemType) For Period ktov:WeightedAverageRemainingContractualLife
749 Number of consultants Concept (Integer) For Period ktov:NumberOfConsultants
750 Key management personnel, description Concept (Text/String) For Period ktov:KeyManagementPersonnelExpensesDescription
751 Share-based compensation expense Concept (Monetary) For Period Debit ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
752 070 - Disclosure - Transactions and Balances with Related Parties (Details) Network

*

*

 http://kitovpharma.com/role/Transactionsandbalanceswithrelatedpartiesdetails
753 Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [table] Table

*

*

 ifrs-full:DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesTable
754 Separate management entities [axis] Axis ifrs-full:SeparateManagementEntitiesAxis
755 Separate management entities [member] Member ifrs-full:SeparateManagementEntitiesMember
756 Payments to Key Management [Member] Member ktov:PaymentsToKeyManagementMember
757 Categories of related parties [axis] Axis ifrs-full:CategoriesOfRelatedPartiesAxis
758 Entity's total for related parties [member] Member ifrs-full:EntitysTotalForRelatedPartiesMember
759 Executive Officers [Member] Member ktov:ChiefExecutivesOfficerMember
760 Directors [Member] Member ktov:DirectorsMember
761 Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items] LineItems ifrs-full:DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems
762 Short - term employee benefits Concept (Monetary) For Period Debit ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits
763 Post-employment benefits Concept (Monetary) For Period Debit ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits
764 Share based payments Concept (Monetary) For Period Debit ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
765 Total Concept (Monetary) For Period Debit ifrs-full:KeyManagementPersonnelCompensation
766 071 - Disclosure - Commitments and Contingent Liabilities (Details) Network

*

*

 http://kitovpharma.com/role/CommitmentsAndContingentLiabilitiesDetails
767 Disclosure of contingent liabilities [table] Table

*

*

 ifrs-full:DisclosureOfContingentLiabilitiesTable
768 Maturity [axis] Axis ifrs-full:MaturityAxis
769 Aggregated time bands [member] Member ifrs-full:AggregatedTimeBandsMember
770 Less than one year [Member] Member ifrs-full:NotLaterThanOneYearMember
771 Between one to five years [Member] Member ktov:BetweenOneToFiveYearMember
772 More than five years [Member] Member ktov:MoreThanFiveYearsMember
773 Disclosure of contingent liabilities [line items] LineItems ifrs-full:DisclosureOfContingentLiabilitiesLineItems
774 Future minimum lease payments under non-cancellable operating leases Concept (Monetary) As Of Credit ifrs-full:MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease
775 072 - Disclosure - Commitments and Contingent Liabilities (Details Textual) Network

*

*

 http://kitovpharma.com/role/CommitmentsAndContingentLiabilitiesDetailsTextual
776 Disclosure of transactions between related parties [table] Table

*

*

 ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesTable
777 Categories of related parties [axis] Axis ifrs-full:CategoriesOfRelatedPartiesAxis
778 Entity's total for related parties [member] Member ifrs-full:EntitysTotalForRelatedPartiesMember
779 Dexcel Ltd. [Member] Member ifrs-full:JointControlOrSignificantInfluenceMember
780 TyrNovo [Member] Member ktov:TyrnovosTechnologyMember
781 Yissum [Member] Member ktov:YissumMember
782 Tranche Type [Axis] Axis ktov:TrancheTypeAxis
783 Tranche Type [Domain] Member ktov:TrancheTypeDomain
784 First Tranche [Member] Member ktov:FirstTrancheMember
785 Second Tranche [Member] Member ktov:SecondTrancheMember
786 Final Tranche [Member] Member ktov:FinalTrancheMember
787 Office premises through to the end of 2020 and for car leases through mid - 2021 [Member] Member ktov:OfficePremisesThroughToEndOfTwoThousandTwentyAndForCarLeasesThroughMidTwoThousandTwentyOneMember
788 Ranges [Axis] Axis ktov:RangesAxis
789 Ranges [Domain] Member ktov:RangesDomain
790 Bottom of range [member] Member ifrs-full:BottomOfRangeMember
791 Top of range [member] Member ifrs-full:TopOfRangeMember
792 Name Of Innovation Authority [Axis] Axis ktov:NameOfInnovationAuthorityAxis
793 Name Of Innovation Authority [Domain] Member ktov:NameOfInnovationAuthorityDomain
794 Israel Innovation Authority [Member] Member ktov:IsraelInnovationAuthorityMember
795 Disclosure of transactions between related parties [line items] LineItems ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesLineItems
796 Commitments and Contingent Liabilities (Textual) Abstract ktov:CommitmentsAndContingentLiabilitiesTextualAbstract
797 Issuance of shares, net of issuance costs Concept (Monetary) For Period Credit ifrs-full:IssueOfEquity
798 Milestone payments Concept (Monetary) For Period Credit ktov:MilestonePayments
799 Payment receive date Concept (Date) For Period ktov:PaymentReceiveDate
800 Annual commitment under lease agreements Concept (Monetary) For Period Credit ktov:LeaseAgreementForOfficePremisesAndCarLeases
801 Bonus amount Concept (Monetary) For Period Debit ktov:BonusIssued
802 Issuance costs of the ADSs Concept (Monetary) As Of Credit ifrs-full:AmountsPayableRelatedPartyTransactions
803 Liability due to grants Concept (Monetary) As Of Credit ifrs-full:NoncurrentProvisionsForEmployeeBenefits
804 Motion total amount Concept (Monetary) For Period Credit ktov:LossContingencyDamagePaidValue
805 Description, of lawsuit filing Concept (Text/String) For Period ktov:LossContingencyLawsuitsFilingDate
806 Loss contingency actions taken by court arbitrator or mediator Concept (Text/String) For Period ktov:LossContingencyActionTakenByCourtArbitratorOrMediator
807 Gains on litigation settlements Concept (Monetary) For Period Credit ifrs-full:GainsOnLitigationSettlements
808 Shareholders maturity date Concept (Text/String) For Period ktov:ShareholdersMaturityDate
809 Number of motions Concept (Integer) As Of ktov:NumberOfMotions
810 Debt instrument offering date Concept (Date) For Period ktov:DebtInstrumentsOfferingDate
811 Weighted average price per share Concept (Share) For Period ktov:WeightedAveragePricePerShare
812 Aggregate amount of grants received Concept (Monetary) As Of Debit ktov:AggregateAmountOfGrantsReceived
813 Maximum royalty payable excluding interest amount Concept (Monetary) For Period Credit ktov:MaximumRoyaltyPayableExcludingInterest
814 Description of license agreement Concept (Text/String) For Period ktov:DescriptionOfLicenseAgreement
815 Annual interest rate of revenues Concept (Percent) For Period ifrs-full:PercentageOfEntitysRevenue
816 Leases bank guarantee fee Concept (Monetary) As Of Debit ktov:LeasesBankGuaranteeFee
817 Aggregate consideration received Concept (Monetary) For Period Credit ktov:AggregateConsiderationReceived
818 Insurance carriers Concept (Monetary) For Period Debit ifrs-full:InsuranceExpense
819 073 - Disclosure - Research and Development Expenses (Details) Network

*

*

 http://kitovpharma.com/role/ResearchandDevelopmentExpensesDetails
820 Implied Table Table

*

*

 implied:Table
821 Research and Development Expenses [Abstract] Abstract ktov:ResearchAndDevelopmentExpensesAbstract
822 Salaries, wages and related expenses Concept (Monetary) For Period Debit ifrs-full:WagesAndSalaries
823 Share-based payments Concept (Monetary) For Period Debit ktov:ShareBasedPayments
824 Service Providers Expenses Concept (Monetary) For Period Debit ktov:ServiceProvidersExpenses
825 Research and development expense Concept (Monetary) For Period Debit ifrs-full:ResearchAndDevelopmentExpense
826 074 - Disclosure - General and Administrative Expenses (Details) Network

*

*

 http://kitovpharma.com/role/GeneralAndAdministrativeExpensesDetails
827 Implied Table Table

*

*

 implied:Table
828 General and Administrative Expenses [Abstract] Abstract ktov:GeneralAndAdministrativeExpensesAbstract
829 Employees and officers compensation Concept (Monetary) For Period Debit ktov:EmployeeAndOfficerCompensation
830 Share-based payments (see also Note 10) Concept (Monetary) For Period Credit ifrs-full:PaymentsForShareIssueCosts
831 Legal fees in connection with ISA investigation and class action lawsuits (see also Note 12B) Concept (Monetary) For Period Debit ktov:LegalFee
832 Other professional consulting Concept (Monetary) For Period Debit ifrs-full:ProfessionalFeesExpense
833 Board member remuneration and insurance Concept (Monetary) For Period Debit ifrs-full:DirectorsRemunerationExpense
834 Rent and office maintenance Concept (Monetary) For Period Debit ifrs-full:RentalExpense
835 Travel Concept (Monetary) For Period Debit ifrs-full:TravelExpense
836 Car expenses Concept (Monetary) For Period Debit ifrs-full:TransportationExpense
837 Depreciation Concept (Monetary) For Period Debit ifrs-full:DepreciationExpense
838 Other Concept (Monetary) For Period Debit ktov:GeneralAndAdministrativeExpensesOther
839 General and Administrative Expenses Concept (Monetary) For Period Debit ifrs-full:SellingGeneralAndAdministrativeExpense
840 075 - Disclosure - General and Administrative Expenses (Details Textual) Network

*

*

 http://kitovpharma.com/role/GeneralAndAdministrativeExpensesDetailsTextual
841 Implied Table Table

*

*

 implied:Table
842 General and Administrative Expenses [Abstract] Abstract ktov:GeneralAndAdministrativeExpensesAbstract
843 General and Administrative Expenses (Textual) Abstract ktov:GeneralAndAdministrativeExpensesTextualAbstract
844 legal expenses Concept (Monetary) For Period Credit ifrs-full:FeeAndCommissionIncome
845 076 - Disclosure - Other Expenses (Income) (Details) Network

*

*

 http://kitovpharma.com/role/OtherExpensesIncomeDetails
846 Implied Table Table

*

*

 implied:Table
847 Other Expenses (Income) [Abstract] Abstract ktov:OthersExpensesAbstract
848 Other Expenses (Income) (Textual) Abstract ktov:OtherExpensesTextualAbstract
849 Other expenses (income) Concept (Monetary) For Period Credit ktov:OtherIncomeExpenseByFunction
850 077 - Disclosure - Finance Expense (Income) (Details) Network

*

*

 http://kitovpharma.com/role/FinanceExpenseIncomeDetails
851 Implied Table Table

*

*

 implied:Table
852 Finance Expense (Income) [Abstract] Abstract ktov:FinanceExpenseIncomeAbstract
853 Net change in fair value of derivatives Abstract ifrs-full:GainsLossesOnChangeInFairValueOfDerivativesAbstract
854 Expenses Concept (Monetary) For Period Debit ifrs-full:LossesOnChangeInFairValueOfDerivatives
855 Income Concept (Monetary) For Period Credit ifrs-full:GainsOnChangeInFairValueOfDerivatives
856 Net change in fair value of derivatives Concept (Monetary) For Period Credit ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives
857 078 - Disclosure - Finance Expense (Income) (Details 1) Network

*

*

 http://kitovpharma.com/role/FinanceExpenseIncomeDetails1
858 Implied Table Table

*

*

 implied:Table
859 Finance Expense (Income) [Abstract] Abstract ktov:FinanceExpenseIncomeAbstract
860 Finance expense Abstract ktov:FinanceExpenseAbstract
861 Fees and interest expense Concept (Monetary) For Period Debit ifrs-full:FeeAndCommissionExpense
862 Loss from exchange rate differences, net Concept (Monetary) For Period Credit ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax
863 Payment to Taoz, see Note 5D Concept (Monetary) For Period Debit ifrs-full:OtherFeeAndCommissionExpense
864 Warrant issuance costs Concept (Monetary) For Period Debit ktov:WarrantIssuanceCosts
865 Finance expense Concept (Monetary) For Period Debit ifrs-full:FinanceCosts
866 Finance income Abstract ktov:FinanceIncomeAbstract
867 Income from exchange rate differences, net Concept (Monetary) For Period Credit ifrs-full:InterestIncomeOnDeposits
868 Interest income from short term deposits Concept (Monetary) For Period Credit ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
869 Finance income Concept (Monetary) For Period Credit ifrs-full:FinanceIncome
870 079 - Disclosure - Taxes on Income (Details) Network

*

*

 http://kitovpharma.com/role/TaxesonIncomeDetails
871 Taxes On Income [Table] Table

*

*

 ktov:TaxesOnIncomeTable
872 Non-adjusting events after reporting period [axis] Axis ifrs-full:NonadjustingEventsAfterReportingPeriodAxis
873 Non-adjusting events after reporting period [member] Member ifrs-full:NonadjustingEventsMember
874 Corporate Tax Rate [Member] Member ktov:CorporateTaxRateMember
875 Changes in tax rates or tax laws enacted or announced [member] Member ifrs-full:ChangesInTaxRatesOrTaxLawsEnactedOrAnnouncedMember
876 Ranges [Axis] Axis ktov:RangesAxis
877 Ranges [Domain] Member ktov:RangesDomain
878 Bottom of range [member] Member ifrs-full:BottomOfRangeMember
879 Top of range [member] Member ifrs-full:TopOfRangeMember
880 Taxes On Income [Line Items] LineItems ktov:TaxesOnIncomeLineItems
881 Taxes on Income (Textual) Abstract ktov:TaxesOnIncomeTextualAbstract
882 Corporate tax rate Concept (Percent) For Period ifrs-full:ApplicableTaxRate
883 Unrecognized research and development expenses Concept (Monetary) As Of Credit ifrs-full:DeferredTaxLiabilities
884 080 - Disclosure - Employee Benefits (Details) Network

*

*

 http://kitovpharma.com/role/EmployeebenefitsDetails
885 Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [table] Table

*

*

 ifrs-full:DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesTable
886 Separate management entities [axis] Axis ifrs-full:SeparateManagementEntitiesAxis
887 Separate management entities [member] Member ifrs-full:SeparateManagementEntitiesMember
888 Post-employment benefits [Member] Member ktov:SeparateManagementEntitieMember
889 Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items] LineItems ifrs-full:DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems
890 Short-term benefits Concept (Monetary) For Period Debit ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits
891 Post-employment benefits Concept (Monetary) For Period Debit ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits
892 081 - Disclosure - Employee Benefits (Details 1) Network

*

*

 http://kitovpharma.com/role/Employeebenefitsdetails1
893 Implied Table Table

*

*

 implied:Table
894 Employee Benefits [Abstract] Abstract ktov:EmployeeBenefitsAbstract
895 Amount recognized as expense in respect of defined contribution plan Concept (Monetary) For Period Debit ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans
896 082 - Disclosure - Financial Instruments (Details) Network

*

*

 http://kitovpharma.com/role/FinancialInstrumentsDetails
897 Disclosure of continuing involvement in derecognised financial assets [table] Table

*

*

 ifrs-full:DisclosureOfContinuingInvolvementInDerecognisedFinancialAssetsTable
898 Continuing involvement in derecognised financial assets by type of instrument [axis] Axis ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis
899 Types of instrument [member] Member ifrs-full:TypesOfInstrumentMember
900 Cash and cash equivalents and deposits [Member] Member ktov:CashAndCashEquivalentsAndDepositsMember
901 Other current assets [Member] Member ktov:OtherCurrentsAssetMember
902 Accounts payable [Member] Member ktov:AccountPayablesMember
903 Other payables [Member] Member ktov:OtherPayablesMember
904 Post-employment benefit liabilities [Member] Member ktov:PostEmploymentBenefitLiabilitiesMember
905 Ranges [Axis] Axis ktov:RangesAxis
906 Ranges [Domain] Member ktov:RangesDomain
907 Down 2% [Member] Member ktov:DownRangeMember
908 Down 5% [Member] Member ktov:DownRangeOneMember
909 Up 5% [Member] Member ktov:UpRangeMember
910 Up 2% [Member] Member ktov:UpRangeOneMember
911 Disclosure of continuing involvement in derecognised financial assets [line items] LineItems ifrs-full:DisclosureOfContinuingInvolvementInDerecognisedFinancialAssetsLineItems
912 Income (loss) from change in exchange rate Concept (Monetary) For Period Credit ktov:IncomeLossFromChangeInExchangeRate
913 Income (loss) value Concept (Monetary) For Period Credit ktov:IncomeLossValue
914 083 - Disclosure - Financial Instruments (Details 1) Network

*

*

 http://kitovpharma.com/role/FinancialInstrumentsDetails1
915 Disclosure of fair value measurement of assets [table] Table

*

*

 ifrs-full:DisclosureOfFairValueMeasurementOfAssetsTable
916 Levels of fair value hierarchy [axis] Axis ifrs-full:LevelsOfFairValueHierarchyAxis
917 All levels of fair value hierarchy [member] Member ifrs-full:AllLevelsOfFairValueHierarchyMember
918 Level 1 [Member] Member ifrs-full:Level1OfFairValueHierarchyMember
919 Level 2 [Member] Member ifrs-full:Level2OfFairValueHierarchyMember
920 Level 3 [Member] Member ifrs-full:Level3OfFairValueHierarchyMember
921 Disclosure of fair value measurement of equity [line items] LineItems ifrs-full:DisclosureOfFairValueMeasurementOfEquityLineItems
922 Warrants Concept (Monetary) As Of Debit ktov:Warrants
923 Put option to Taoz (see Note 5B) Concept (Monetary) As Of Debit ktov:PutOptions
924 Financial liabilities Concept (Monetary) As Of Credit ifrs-full:FinancialLiabilities
925 084 - Disclosure - Financial Instruments (Details 2) Network

*

*

 http://kitovpharma.com/role/FinancialInstrumentsDetails2
926 Disclosure of continuing involvement in derecognised financial assets [table] Table

*

*

 ifrs-full:DisclosureOfContinuingInvolvementInDerecognisedFinancialAssetsTable
927 Continuing involvement in derecognised financial assets by type of instrument [axis] Axis ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis
928 Types of instrument [member] Member ifrs-full:TypesOfInstrumentMember
929 Warrants [Member] Member ktov:WarrantsMember
930 Investment and Put option to Taoz [Member] Member ktov:InvestmentAndPutOptionMember
931 Valuation techniques used in fair value measurement [axis] Axis ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis
932 Valuation techniques [member] Member ifrs-full:ValuationTechniquesMember
933 Black - Scholes [Member] Member ktov:BlackScholesMember
934 Monte - Carlo Simulation [Member] Member ktov:MonteCarloSimulationMember
935 Ranges [Axis] Axis ktov:RangesAxis
936 Ranges [Domain] Member ktov:RangesDomain
937 Top of range [member] Member ifrs-full:TopOfRangeMember
938 Bottom of range [member] Member ifrs-full:BottomOfRangeMember
939 Disclosure of continuing involvement in derecognised financial assets [line items] LineItems ifrs-full:DisclosureOfContinuingInvolvementInDerecognisedFinancialAssetsLineItems
940 expected term Concept (xbrli:durationItemType) For Period ktov:SignificantUnobservableInputsExpectedTerm
941 expected volatility Concept (Percent) For Period ktov:SignificantUnobservableInputsExpectedVolatility
942 annual risk free interest Concept (Percent) For Period ktov:SignificantUnobservableInputsAnnualRiskFreeInterest
943 dividend yield Concept (Percent) For Period ktov:SignificantUnobservableDividendYield
944 Valuation at milestone Concept (Monetary) For Period Debit ktov:SignificantUnobservableValuationAtMilestone
945 Share Price Concept (Monetary) For Period Debit ktov:SignificantUnobservableSharePrice
946 Probability of reaching milestone Concept (Percent) For Period ktov:SignificantUnobservableProbabilityOfReachingMilestone
947 085 - Disclosure - Financial Instruments (Details Textual) Network

*

*

 http://kitovpharma.com/role/FinancialInstrumentsDetailsTextual
948 Disclosure of detailed information about borrowings [table] Table

*

*

 ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsTable
949 Ranges [Axis] Axis ktov:RangesAxis
950 Ranges [Domain] Member ktov:RangesDomain
951 Bottom of range [member] Member ifrs-full:BottomOfRangeMember
952 Top of range [member] Member ifrs-full:TopOfRangeMember
953 Disclosure of detailed information about borrowings [line items] LineItems ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsLineItems
954 Financial Instruments (Textual) Abstract ktov:FinancialInstrumentsTextualAbstract
955 Cash and cash equivalents and short term deposits Concept (Monetary) As Of Debit ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents
956 Short term deposits fixed interest rate Concept (Percent) As Of ifrs-full:BorrowingsInterestRate
957 086 - Disclosure - Subsequent Events (Details) Network

*

*

 http://kitovpharma.com/role/SubsequentEventsDetails
958 Disclosure of detailed information about business combination [table] Table

*

*

 ifrs-full:DisclosureOfBusinessCombinationsTable
959 Categories of related parties [axis] Axis ifrs-full:CategoriesOfRelatedPartiesAxis
960 Entity's total for related parties [member] Member ifrs-full:EntitysTotalForRelatedPartiesMember
961 TyrNovo [Member] Member ktov:TyrNovoLtdMember
962 Kitov [Member] Member ktov:KitovMember
963 Taoz [Member] Member ktov:TaozMember
964 Coeptis Pharmaceuticals Inc. [Member] Member ktov:CoeptisPharmaceuticalsIncMember
965 Famewave Ltd [Member] Member ktov:FamewaveLtdMember
966 Components of equity [axis] Axis ifrs-full:ComponentsOfEquityAxis
967 Equity [member] Member ifrs-full:EquityMember
968 ADS [Member] Member ktov:AdsMember
969 NASDAQ [Member] Member ktov:NasdaqMember
970 Non-adjusting events after reporting period [axis] Axis ifrs-full:NonadjustingEventsAfterReportingPeriodAxis
971 Non-adjusting events after reporting period [member] Member ifrs-full:NonadjustingEventsMember
972 January 2019 [Member] Member ktov:NonadjustingEventsOneMember
973 January 2, 2019 [Member] Member ktov:NonadjustingEventsTwoMember
974 March 14, 2019 [Member] Member ktov:NonadjustingEventsThreeMember
975 March 2019 [Member] Member ktov:NonadjustingEventsFourMember
976 Disclosure of detailed information about business combination [line items] LineItems ifrs-full:DisclosureOfBusinessCombinationsLineItems
977 Subsequents Event (Textual) Abstract ktov:SubsequentsEventTextualAbstract
978 Gross amount of placement agent fees Concept (Monetary) For Period Debit ktov:GrossOfPlacementAgentFees
979 Net of placement agent fees and other offering related expenses Concept (Monetary) For Period Debit ktov:NetOfPlacementAgentFeesAndOtherOfferingRelatedExpenses
980 Direct offering description Concept (Text/String) For Period ktov:DirectOfferingDescription
981 Agreement description Concept (Text/String) For Period ktov:AgreementDescription
982 Agreement to acquire description Concept (Text/String) For Period ktov:AgreementToAcquireDescription
983 Options to granted, description Concept (Text/String) For Period ktov:OptionsToGrantedDescription

*

*